JP2021517894A5 - - Google Patents

Info

Publication number
JP2021517894A5
JP2021517894A5 JP2020548775A JP2020548775A JP2021517894A5 JP 2021517894 A5 JP2021517894 A5 JP 2021517894A5 JP 2020548775 A JP2020548775 A JP 2020548775A JP 2020548775 A JP2020548775 A JP 2020548775A JP 2021517894 A5 JP2021517894 A5 JP 2021517894A5
Authority
JP
Japan
Prior art keywords
inhibitor
composition according
pharmaceutical composition
cancer
cdk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548775A
Other languages
English (en)
Japanese (ja)
Other versions
JP7698418B2 (ja
JP2021517894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022067 external-priority patent/WO2019178239A1/en
Publication of JP2021517894A publication Critical patent/JP2021517894A/ja
Publication of JP2021517894A5 publication Critical patent/JP2021517894A5/ja
Priority to JP2025013551A priority Critical patent/JP2025069282A/ja
Application granted granted Critical
Publication of JP7698418B2 publication Critical patent/JP7698418B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548775A 2018-03-13 2019-03-13 Ｅｇｆｒ活性化変異を有するがんを治療するための方法 Active JP7698418B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013551A JP2025069282A (ja) 2018-03-13 2025-01-30 Ｅｇｆｒ活性化変異を有するがんを治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642472P 2018-03-13 2018-03-13
US62/642,472 2018-03-13
PCT/US2019/022067 WO2019178239A1 (en) 2018-03-13 2019-03-13 Methods for treatment of cancers with egfr activating mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013551A Division JP2025069282A (ja) 2018-03-13 2025-01-30 Ｅｇｆｒ活性化変異を有するがんを治療するための方法

Publications (3)

Publication Number Publication Date
JP2021517894A JP2021517894A (ja) 2021-07-29
JP2021517894A5 true JP2021517894A5 (enExample) 2022-03-22
JP7698418B2 JP7698418B2 (ja) 2025-06-25

Family

ID=67908486

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548775A Active JP7698418B2 (ja) 2018-03-13 2019-03-13 Ｅｇｆｒ活性化変異を有するがんを治療するための方法
JP2025013551A Withdrawn JP2025069282A (ja) 2018-03-13 2025-01-30 Ｅｇｆｒ活性化変異を有するがんを治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013551A Withdrawn JP2025069282A (ja) 2018-03-13 2025-01-30 Ｅｇｆｒ活性化変異を有するがんを治療するための方法

Country Status (5)

Country Link
US (1) US20210015819A1 (enExample)
JP (2) JP7698418B2 (enExample)
KR (1) KR20200132902A (enExample)
CN (1) CN111867586A (enExample)
WO (1) WO2019178239A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078006B (zh) 2016-03-29 2021-04-20 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
AU2020254499A1 (en) * 2019-03-29 2021-10-28 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 insertions
US20230293414A1 (en) * 2020-08-07 2023-09-21 Hope Permanente, Llc Use of cyclin-dependent kinase (cdk) inhibitors for the slowdown or prevention of biological aging
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN114432454B (zh) * 2022-03-21 2023-05-05 安徽大学 Plk1抑制剂在制备治疗埃博拉病毒疾病的药物中的应用
AU2023248394A1 (en) 2022-04-08 2024-10-31 Baerenkraft Therapeutics, Llc Cdk9 inhibitors
CN114869890A (zh) * 2022-04-22 2022-08-09 南京市儿童医院 一种plk1抑制剂在制备用于缓解肾脏纤维化药物中的用途
WO2024192141A1 (en) * 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2025245045A1 (en) * 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) * 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
WO2007077435A1 (en) * 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
EA014231B1 (ru) * 2006-02-10 2010-10-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Комбинации, включающие ингибитор cdk и антитело фактора роста или антимитотик
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
ES2529790T3 (es) * 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
CA2707424A1 (en) * 2007-11-28 2009-06-04 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20140155397A1 (en) * 2011-04-01 2014-06-05 Board Of Regents Emt signatures and predictive markers and method of using the same
ES2655842T3 (es) * 2012-04-18 2018-02-21 Cell Signaling Technology, Inc. EGFR y ROS1 en el cáncer
US20140121126A1 (en) * 2012-10-25 2014-05-01 Memorial Sloan-Kettering Cancer Center Methods of detecting axl and gas6 in cancer patients
JP6678584B2 (ja) * 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
WO2015112705A2 (en) * 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
US20160346240A1 (en) * 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
EP3148532B1 (en) * 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
EP3307728A4 (en) * 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
US10240145B2 (en) * 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
GB201612520D0 (en) * 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20190275049A1 (en) * 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
CN110325191A (zh) * 2017-02-22 2019-10-11 G1治疗公司 以较少的副作用治疗egfr-驱动的癌症
WO2019090332A1 (en) * 2017-11-06 2019-05-09 Tiziana Life Sciences Plc Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

Similar Documents

Publication Publication Date Title
Grech et al. EPMA position paper in cancer: current overview and future perspectives
Kodaz et al. Frequency of RAS mutations (KRAS, NRAS, HRAS) in human solid cancer
JP2022529016A5 (enExample)
JP2022527788A5 (enExample)
JP2022515705A (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法
BR112016008016B1 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditoscompostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ounras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dosditos compostos
CN104781423A (zh) 对胃癌进行分类的分组方法
CA2850175C (en) Biomarkers for predicting sensitivity to cancer treatments
Moran et al. Identification of fusions with potential clinical significance in melanoma
Huang et al. CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation
CN114540500A (zh) 评价乳腺癌患者整体生存的产品
JP2022527499A5 (enExample)
JP2021519306A5 (enExample)
US20220305008A1 (en) Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
JP2022515128A5 (enExample)
JP2007513967A (ja) 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
Martinelli et al. New targets for Ph+ leukaemia therapy
Kozlov et al. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report
Chen et al. The signature of immune-subtype specific driving transcription factors suggest potential drugs for refractory glioblastoma
Jin-Fei et al. Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Su et al. Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China
CN107841793A (zh) 肺癌多基因突变文库的构建方法
O'Byrne et al. 17P examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma
Sun et al. NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma
CN105566329A (zh) 一种吡唑[5，6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性